PT  - JOURNAL ARTICLE
AU  - Peach, Emily
AU  - Rutter, Megan
AU  - Lanyon, Peter
AU  - Grainge, Matthew J
AU  - Hubbard, Richard
AU  - Aston, Jeanette
AU  - Bythell, Mary
AU  - Stevens, Sarah
AU  - Pearce, Fiona
TI  - Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. Preliminary results from the RECORDER project
AID  - 10.1101/2020.10.09.20210237
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.09.20210237
4099  - http://medrxiv.org/content/early/2020/10/11/2020.10.09.20210237.short
4100  - http://medrxiv.org/content/early/2020/10/11/2020.10.09.20210237.full
AB  - Objectives To quantify the risk of death among people with rare autoimmune rheumatic diseases (RAIRD) during the UK 2020 COVID-19 epidemic compared with baseline risk and the risk of death in the general population during COVID-19.Design A cohort study using data from the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS). We used ONS published data for general population mortality rates.Setting Hospital Episode Statistics for England 2003 onwards, and linked data from the NHS Personal Demographics Service.Participants 168,691 people with RAIRD who were alive on 1 March 2020. Their median age was 61.7 (IQR 41.5-75.4) years, and 118,379 (70.2%) were female. Our case ascertainment methods had a positive predictive value >85%.Main outcome measure Age-standardised mortality rates for all-cause death. Secondary outcome measures were age-sex standardised mortality rates, and age-stratified mortality rates.Results 1,815 (1.1%) participants died during March and April 2020. The age-standardised mortality rate (ASMR) among people with RAIRD (3669.3, 95% CI 3500.4-3838.1 per 100,000 person-years) was 1.44 (95% CI 1.42-1.45) times higher than the average ASMR during the same months of the previous 5 years, whereas in the general population of England it was 1.38 times higher. Compared to the general population, the age-specific mortality rates in people with RAIRD compared to the pre-COVID rates were higher from the age of 35 upwards, whereas in the general population the increased risk began from age 55 upwards. Sex-specific rates were similar in males and females, whereas in the general population females had a lower rate than males.Conclusions The risk of all-cause death is more prominently raised during COVID-19 among people with RAIRD than among the general population. We urgently need to quantify how much risk is due to COVID-19 infection and how much is due to disruption to healthcare services, in order to inform better guidance about shielding, access to healthcare and vaccine priorities for people with rare diseases.What is already known on this topic?People with rare diseases often suffer worse health outcomes than people with more common diseases. Little is known about the risks to people with rare diseases during COVID-19. The OPENSAFELY study found people with common autoimmune diseases were at little increased risk due to COVID-19.What this study adds This is the first study to quantify the risk of death among people with rare autoimmune rheumatic diseases (RAIRD) during COVID-19.People with rare autoimmune rheumatic diseases (RAIRD) had an increased risk of death compared to their pre-COVID risk that is slightly higher than in the general population.People with RAIRD had an increased risk of death, compared to their pre-COVID risk, from age 35 upwards, whereas in the general population the increased risk occurred from around age 55 upwards. Because females and males with RAIRD had similar age-standardised mortality rates during COVID-19, but females had lower rates pre-COVID and in the general population during COVID-19, the group at the largest increase of risk compared to their pre-COVID-19 risk were women aged 35 upwards.We urgently need to quantify how much risk is due to COVID-19 infection and how much due to disruption to healthcare services to inform better shielding advice, prioritisation of healthcare services, and vaccine priorities for people with rare diseases.Competing Interest StatementEP, FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.Funding StatementThis study received funding for MR from Vasculitis UK (patient charity). EP, FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received a favourable opinion from the Camden and Kings Cross Research Ethics Committee, study reference 20/HRA/2076, on 18 June 2020. Data were accessed and processed under section 251 permission granted to NCARDRS CAG 10-02(d)/2015).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNCARDRS data are available to all who have a legal basis to access them. Further information is available at by application to Public Health England Office for data release (Available from www.gov.uk/government/publications/accessing-public-health-england-data/about-the-phe-odr-and-accessing-data [cited 2020 Oct 9])